Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis
Ke-Yu Shen, Shi-Zhe Yu, Ying-Han Su, Sun-Zhe Xie, Chen Zhang, Hao Xu, SamI Yang, Tian-Tian Zou, Yan Fu, Hao Wang, Lin Fang, Yan Zheng, Chang-Qing Su, Lun-Xiu Qin · 2025
Read Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis by Ke-Yu Shen, Shi-Zhe Yu, Ying-Han Su, Sun-Zhe Xie, Chen Zhang, Hao Xu, SamI Yang, Tian-Tian Zou, Yan Fu, Hao Wang, Lin Fang, Yan Zheng, Chang-Qing Su, Lun-Xiu Qin (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12722228.txt.
Description
Tumors with few mutations give the immune system little to recognize, so immune drugs often fail against them. Ke-Yu Shen and co-authors used a cancer-killing virus to change that in this 2025 study. The virus was a rebuilt adenovirus that infects tumor cells and makes them display neoantigens, the odd proteins that flag a cell as cancerous. Those flags can wake up immune attack.
In a liver bile-duct cancer model with few mutations, the virus beat a standard peptide vaccine. A stronger version, called NeoViron, also made a factor that draws in dendritic cells, the immune system's scouts. That pairing boosted both flag display and T cell entry into the tumor. Growth slowed, and the team reports the approach also blocked spread. Quiet tumors may need such a loud wake-up call.
Catalog record
| CREATOR | Ke-Yu Shen, Shi-Zhe Yu, Ying-Han Su, Sun-Zhe Xie, Chen Zhang, Hao Xu, SamI Yang, Tian-Tian Zou, Yan Fu, Hao Wang, Lin Fang, Yan Zheng, Chang-Qing Su, Lun-Xiu Qin |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |